Guowen Liu

Guowen Liu has a comprehensive work experience in bioanalytical and biomarker development spanning multiple companies. Starting in 2005 at Bristol-Myers Squibb, they worked their way up from Research Investigator roles to Sr. Research Investigator II, specializing in regulated bioanalysis. At Bristol-Myers Squibb, Guowen led internal scientists in providing bioanalytical support for clinical and toxicity studies, developed and validated bioanalytical assays, managed internal scientists, and interacted with CROs for bioanalytical support.

In 2016, Guowen joined Agios Pharmaceuticals as Associate Director-DMPK-Bioanalysis, responsible for bioanalytical support for discovery and development programs, managing the internal bioanalytical laboratory, planning and managing resources, working with CROs, and ensuring compliance with regulatory requirements. They were later promoted to Director and became Head of Bioanalysis, leading two bioanalytical groups and providing support for all Agios programs.

Moving on to Kymera Therapeutics in 2021, Guowen held the role of Sr. Director of Bioanalytical and Biomarker Development until 2022. Currently, they are the Sr. Director and Head of Bioanalytical and Biomarker Development at Disc Medicine, starting in May 2022.

Guowen Liu holds a Bachelor's Degree in Chemistry from Tsinghua University. Guowen also pursued further education at Tsinghua University, where they obtained a Master's Degree in Analytical Chemistry. Later, they pursued a Ph.D in Medicinal Chemistry from the University of Illinois Chicago. No specific start or end years are provided for any of these educational experiences.